Hernix (neratinib)

Description

Hernix (neratinib)

Niratinib is an oral, irreversible tyrosine kinase inhibitor. It is the only product in the world approved for intensive adjuvant therapy after treatment with HER2-positive breast cancer with trastuzumab (Herceptin) to reduce the risk of recurrence. The applicable population is to complete the standard trastuzumab adjuvant treatment of patients with undeveloped disease but high-risk factors.

Indications:

For breast cancer patients who have completed standard trastuzumab (Herceptin, Herceptin) adjuvant therapy, disease progression, but high-risk factors

Product Name               : Hernix

Generic Name               : Neratinib
Formulation: Tablet
Available Pack size      : 180 tablets

Strengths                       : 40 mg